{"id":"W4292148526","doi":"10.1212/wnl.0000000000201029","title":"Disease Reactivation After Cessation of Disease-Modifying Therapy in Patients With Relapsing-Remitting Multiple Sclerosis","year":2022,"lang":"en","type":"article","venue":"Neurology","topic":"Multiple Sclerosis Research Studies","field":"Medicine","cited_by":46,"is_retracted":false,"has_abstract":true,"ca_institutions":"","funders":"National Health and Medical Research Council; Canadian Institutes of Health Research; Sanofi Genzyme; MedDay Pharmaceuticals; Centre Hospitalier Universitaire de Rennes; EMD Serono; Multiple Sclerosis International Federation; Università di Catania; Agence Nationale de la Recherche; National Security Agency; European Committee for Treatment and Research in Multiple Sclerosis; Fondation pour l'Aide à la Recherche sur la Sclérose en Plaques; Multiple Sclerosis Australia; Teva Pharmaceutical Industries; Biogen; Celgene; Fondazione Italiana Sclerosi Multipla; Sanofi","keywords":"Discontinuation; Medicine; Fingolimod; Natalizumab; Multiple sclerosis; Internal medicine; Retrospective cohort study; Cohort; Pediatrics; Disease; Immunology","routes":{"ca_aff":false,"ca_fund":true,"ca_venue":false,"about_ca":false,"invisible_to_affiliation_only":true},"retraction":null,"screen":null,"direct_labels":[],"prediction":{"model_version":"codex-gemma-dda1882f352a","candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.0002133354,0.0001247833,0.0002261687,0.000249726,0.0001282582,0.000005686052,0.00007801638,0.00002731812,0.00007234413],"category_scores_gemma":[0.0005289447,0.0001080875,0.00004875689,0.0003267881,0.00009388015,0.0001074651,0.0001249002,0.0003382417,0.000001101979],"about_ca_system_candidate":false,"about_ca_system_consensus":false,"about_ca_system_score_codex":0.00007258452,"about_ca_system_score_gemma":0.00007083023,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_topic_score_codex":0.0001061988,"about_ca_topic_score_gemma":0.00001619011,"domain_scores_codex":[0.9983253,0.0002664537,0.0002640268,0.00035071,0.0005313158,0.0002622343],"domain_scores_gemma":[0.9990795,0.0002570418,0.0001435105,0.0002815207,0.0001220703,0.0001164034],"domain_codex":null,"domain_gemma":null,"domain_candidate":null,"domain_consensus":null,"study_design_codex":"observational","study_design_gemma":"observational","study_design_scores_codex":[0.02531748,0.0005534555,0.9660199,0.00004322736,0.0000233772,0.000008725126,0.0003026832,0.0005431377,0.001633512,0.00000279725,0.00002698972,0.005524709],"study_design_scores_gemma":[0.005456638,0.001149941,0.9916187,0.0000440511,0.00001596314,1.851588e-7,0.00001845996,0.001387466,0.00007991098,0.00001319523,0.000135828,0.00007965707],"study_design_candidate":"observational","study_design_consensus":"observational","genre_codex":"empirical","genre_gemma":"empirical","genre_scores_codex":[0.997614,0.0001104691,0.00001972678,0.001327866,0.00008004386,0.000748302,0.00003342514,0.00003012799,0.00003601908],"genre_scores_gemma":[0.9987477,0.0000801694,0.00005959896,0.0006104056,0.00003283147,0.0003586869,0.00007500163,0.00002802073,0.000007572651],"genre_candidate":"empirical","genre_consensus":"empirical","teacher_disagreement_score":0.02559879,"threshold_uncertainty_score":0.440768,"prediction_status":"machine_predicted_unvalidated"},"machine_scores":{"provisional":true,"baseline":true,"maturity_gate_passed":false,"score_opus":0.042825921262753,"score_gpt":0.2665634192110927,"score_spread":0.2237374979483397,"validation_status":"score_only:v0-immature-baseline","note":"Baseline scores from an immature model (maturity gate not passed). Scores rank; they never assert a category."}}